drugset / Trial / NCT00003457

Antineoplaston Therapy in Treating Patients With Brain Tumors

NCT00003457

Phase 2 Completed 40 enrolled Burzynski Research Institute
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Current therapies for adults with persistent or recurrent brain tumors provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults with persistent or recurrent brain tumors. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adults with persistent or recurrent brain tumors.

Timeline

Start
1996-07
Primary completion
2012-02
Completion
2012-02

Publications

  • Background Burzynski SR, Janicki TJ, Burzynski GS. A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Primary Brain Tumors-Final Report (Protocol BT-09). Journal of Cancer Therapy 6(12): 1063-1074, 2015. DOI: 10.4236/jct.2015.612116

Drugs

EvaluationDrugModalityDoseRoute
Subject Astugenal Unknown Intravenous
Subject antineoplaston A10 Small molecule Intravenous